← Back to Search

Other

LX9211 for Postherpetic Neuralgia (RELIEF-PHN1 Trial)

Phase 2
Waitlist Available
Research Sponsored by Lexicon Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to week 6
Awards & highlights

Summary

This trial looks at whether LX9211 can reduce pain related to postherpetic neuralgia better than a placebo.

Eligible Conditions
  • Postherpetic Neuralgia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to week 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to week 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in Average Daily Pain Score (ADPS)
Secondary outcome measures
Safety: number of AEs reported
≥30 percent reduction in pain intensity
≥50 percent reduction in pain intensity

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LX9211Experimental Treatment1 Intervention
Following a 2-week Single-blind Run-in period, participants will receive a single loading dose of 200 milligrams (mg) tablet, orally, on Day 1 and maintenance doses of 20 mg, orally, once daily from Day 2 to Week 6.
Group II: PlaceboPlacebo Group1 Intervention
Following a 2-week Single-blind Run-in period, participants will receive a single loading dose of matching-placebo to LX9211 tablet, orally, on Day 1 and maintenance doses, orally, once daily from Day 2 to Week 6.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LX9211
2020
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

Lexicon PharmaceuticalsLead Sponsor
64 Previous Clinical Trials
23,831 Total Patients Enrolled
Suman Wason, MDStudy DirectorLexicon Pharmaceuticals
25 Previous Clinical Trials
16,879 Total Patients Enrolled
Suma Gopinathan, PhDStudy DirectorLexicon Pharmaceuticals
1 Previous Clinical Trials
319 Total Patients Enrolled
~18 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top